Riluzole in the Treatment of Bipolar Depression
| Status: | Completed |
|---|---|
| Conditions: | Depression, Depression, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 8/9/2018 |
| Start Date: | June 2007 |
| End Date: | July 2009 |
Riluzole in the Treatment of Bipolar Depression: A Study of the Association Between Clinical Response and Change in Brain Glutamate Levels as Measured by Proton Magnetic Resonance Spectroscopy
Bipolar disorder is a common and often chronic and debilitating mental illness. The
depressive phase of bipolar disorder contributes the largest portion of the disorder, and
treatment resistant bipolar depression represents a significant public health problem. Recent
research has suggested that bipolar depression is associated with elevated brain glutamate
activity. We hypothesize that riluzole, a drug approved for ALS which inhibits glutamate
activity, will lead to clinical improvement in patients with bipolar depression.
depressive phase of bipolar disorder contributes the largest portion of the disorder, and
treatment resistant bipolar depression represents a significant public health problem. Recent
research has suggested that bipolar depression is associated with elevated brain glutamate
activity. We hypothesize that riluzole, a drug approved for ALS which inhibits glutamate
activity, will lead to clinical improvement in patients with bipolar depression.
We hypothesize that riluzole will lead to significant reduction in depressive symptoms as
measured by the Hamilton Depression Rating Scale (HAM-D). Additionally, improvement in
depressive symptoms will be associated with reduced glutamate levels in the anterior
cingulate cortex, but not parieto-occipital cortex, both at day two and day 42.
measured by the Hamilton Depression Rating Scale (HAM-D). Additionally, improvement in
depressive symptoms will be associated with reduced glutamate levels in the anterior
cingulate cortex, but not parieto-occipital cortex, both at day two and day 42.
Inclusion Criteria:
- Male or female age 18-65
- Meets DSM-IV criteria for Bipolar Disorder and is currently depressed
- Current score of >/= 18 on the Hamilton Depression Scale
Exclusion Criteria:
- Active psychotic/manic symptoms
- Lifetime history of schizophrenia or obsessive compulsive disorder
- Clinically significant medical disease
- Women who are pregnant or lactating and women who are not using a medically accepted
method of contraception.
We found this trial at
1
site
McLean Hospital McLean Hospital is a comprehensive psychiatric hospital committed to providing easy access to...
Click here to add this to my saved trials
